Manufacturing & Packaging

The deal is expected to help boost supply of Wegovy.

An analysis of the two main new models for pharmacy—unique direct—to-consumer for brands and cash pay for generics—and what members of industry think about them.

Leading experts in the sector explore the value of third-party logistics providers when it comes to fortifying pharmaceutical supply chains.

Duplicate rebates have resulted in revenue leakage for manufacturers.

As a result, time to treatment for the brand Gilead product is expected to increase from 16 to 14 days.

The pharmaceutical packaging company unveils a new siliconization line at its SQLM plant in France.

The latest financial commitment adds 24,000 liters of biologics drug substance-capacity to the company’s network.

The Identification of Medicinal Product framework seeks to establish a common language for identifying, documenting, and exchanging information about medicinal products.

Acquisition is expected to strengthen company’s CDMO business, while establishing a footprint in the generics space.

Roots Analysis report suggests increase can be attributed to the growing demand for advanced therapies and biologics.

Manufacturers should leverage the knowledge base of personnel working in sterility assurance and in microbiology laboratories.

Review article explores the latest developments surrounding expression and purification strategies.

In the midst of being approved for commercial manufacturing of Pluvict, the 70,000 square-foot site was built specifically to accommodate RLT production.

Provider’s Pithampur facility is recognized for its use of Industry 4.0 technology.

Popular works in the category explore 340B guidelines, ‘smart pharma’ capabilities, and commercialization trends.

The most popular pieces pertaining to the supply chain featured ADMs, vaccine supply chains, and wholesalers.

Study analyzes and predicts how conditions in research and development can be predicted via computer simulation.

While new forms of pharmacy continue to surface beyond brick-and-mortar retail, a look at what is driving this shift in perspective—and "pharmacies of the future"—is warranted.

The CDMO’s GMP plant will dedicate 2,500 square feet to the storage of finished products.

Parties will provide processing and packaging machinery services.

Blue Fin Group exec speaks on his upcoming feature.

SVP and Managing Director for Blue Fin Group offers a synopsis of the conference opener.

Berkeley Research Group executive speaks about the role of manufacturers in 340B pricing.

R&D teams need to accelerate how they conduct their research, get to a material, and get to market.

Determination will affect future vaccine cost and accessibility, including in developing countries.

MarketsandMarkets report points to growth of over $3 billion over the next five years.

How setting action-based goals and cultivating partnerships will help overcome challenges associated with implementing a sustainable GHG strategy.

Parties will establish a Center of Excellence in CMIC’s NJ plant.

Northern Ireland hub undergoes $85 million expansion.

CDMO predicts that its facilities can now potentially produce over $400 million in annual revenue.